

IN THE CLAIMS:

Please cancel claims 84 and 132 and please amend claims 127 and 140-153 as follows:

1-74. (Cancelled)

75. (Previously presented) A pharmaceutical combination comprising 28 daily sequential dosages, said product including 21 sequential daily hormone dosages, with each hormone dosage comprising a progestin product and an estrogen product and with at least one of said hormone dosages further comprising a Vitamin D compound, and said product further including 7 other daily dosages that do not contain either estrogen and/or progestin and wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

76. (Previously presented) The combination of claim 75 wherein the Vitamin D compound is 1,25 (OH)2 Vitamin D₃ (calcitriol).

77. (Previously presented) The combination of claim 75 wherein the Vitamin D compound is Vitamin D₃ (cholecalciferol).

78. (Previously presented) The combination of claim 75 wherein said estrogen product is ethinyl estradiol.

79. (Previously presented) The combination of claim 78 wherein the daily dosage of said ethinyl estradiol is less than or equal to 0.050 mg and greater than or equal to 0.020 mg.

80. (Previously presented) The combination of claim 75 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 400 I.U.

81. (Previously presented) The combination of claim 80 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 2000 I.U.

82. (Previously presented) The combination of claim 81 wherein the dosage of said Vitamin D compound in at least one of said hormone dosages is equivalent to at least 4000 I.U.

83. (Previously presented) The combination of claim 75 wherein said product is adapted for daily administration of said Vitamin D compound with each said daily hormone dosage.

84. (cancelled)

85. (Previously presented) The combination of claim 75 wherein said progestin product is a gonane.

86. (Previously presented) The combination of claim 75 wherein said progestin product is a pregnane.

87. (Previously presented) The combination of claim 75 wherein said progestin product is a estrane.

88. (Previously presented) The combination of claim 75 wherein said progestin product is norgestimate.

89. (Previously presented) The combination of claim 88 wherein said the estrogen product is ethinyl estradiol and the daily dosage of said ethinyl estradiol is less than or equal to 0.035 mg and greater than or equal to 0.020 mg.

90. (Previously presented) The combination of claim 75 wherein at least one Vitamin D compound is in a single unit dosage with one dosage of said progestin product.

91-124. (Cancelled)

125. (Previously presented) A pharmaceutical combination comprising 21 sequential daily dosages, said 21 daily dosages comprising a progestin product and/or an estrogen product, with at least one of said daily dosages further comprising a Vitamin D compound that does not have hydroxylation at both the 1 and 25 positions and wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

126. (Previously presented) The combination of claim 125 wherein said Vitamin D compound is Vitamin D₂ (ergocalciferol).

127. (Currently amended) The combination of claim 126 wherein the Vitamin D compound is ~~1,25(OH)2~~ Vitamin D₃ (calcidiol cholecalciferol).

128. (Previously presented) The combination of claim 127 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

129. (Previously presented) The combination of claim 125 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

130. (Previously presented) The combination of claim 125 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

131. (Previously presented) The combination of claim 125 wherein said product is adapted for daily administration of said Vitamin D compound with each daily hormone dosage.

132. (cancelled)

133. (Previously presented) The combination of claim 125 wherein said estrogen product is conjugated equine estrogen.

134. (Previously presented) The combination of claim 128 wherein the dosage of said conjugated equine estrogen 0.625 mg.

135 (Previously presented) The combination of claim 125 wherein said estrogen product is estrodiol.

136. (Previously presented) The combination of claim 125 wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.

137. (Previously presented) The combination of claim 125 wherein the daily dosage equivalent of said progestin product is less than or equal to 2.5 mg of medroxyprogesterone acetate daily.

138. (Previously presented) The combination of claim 125 wherein said Vitamin D compound is in a single unit dosage with said progestin product and/or estrogen product.

139. (Previously presented) A pharmaceutical combination comprising 21 sequential daily dosages, said 21 daily dosages comprising a progestin product and/or an estrogen product, with at least one of said daily dosages further comprising a Vitamin D compound, and wherein said product is adapted for administration of said Vitamin D compound on a less frequently than daily basis.

140. (Currently amended) The combination of claim 134 139 wherein said Vitamin D compound is Vitamin D₂ (ergocalciferol).

141. (Currently amended) The combination of claim 134 139 wherein the Vitamin D compound is Vitamin D₃ (cholecalciferol).

142. (Currently amended) The combination of claim 134 139 wherein said Vitamin D compound is calcitriol.

143. (Currently amended) The combination of claim 134 139 wherein the dosage of said Vitamin D compound is equivalent to at least 400 I.U.

144. (Currently amended) The combination of claim 134 139 wherein the dosage of said Vitamin D compound is equivalent to at least 2000 I.U.

145. (Currently amended) The combination of claim 134 139 wherein the dosage of said Vitamin D compound is equivalent to at least 4000 I.U.

146. (Currently amended) The combination of claim ~~134~~ 139 wherein said progestin product is a gonane.

147. (Currently amended) The combination of claim ~~134~~ 139 wherein said progestin product is an estrane.

148. (Currently amended) The combination of claim ~~134~~ 139 wherein said progestin product is a progesterone

149. (Currently amended) The combination of claim ~~134~~ 139 wherein said the estrogen product is conjugated equine estrogen.

150. (Currently amended) The combination of claim ~~134~~ 139 wherein the dosage of said conjugated equine estrogen is 0.625 mg.

151. (Currently amended) The combination of claim ~~134~~ 139 wherein said estrogen product is estradiol.

152. (Currently amended) The combination of claim ~~134~~ 139 wherein the daily dosage equivalent of said progestin product is less than or equal to 10 mg of norethindrone.

153. (Currently amended) The combination of claim ~~134~~ 139 wherein the daily dosage equivalent of said progestin product is less than or equal to 2.5 mg of medroxyprogesterone acetate daily.